Market Overview

Deutsche Analysts React To Bristol-Myers Clinical Trial Disappointment

Share:
Deutsche Analysts React To Bristol-Myers Clinical Trial Disappointment

Deutsche Bank has cut its estimates and price target on Bristol-Myers Squibb Co (NYSE: BMY) shares following its clinical trial disappointment.

Bristol-Myers said on Friday that its CheckMate-026 Study, which was investigating the use of Opdivo (nivolumab) as monotherapy, failed to meet its primary endpoint of progression-free survival in patients with previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed PD-L1 at ≥ 5 percent.

Related Link: CheckMate Miss Is A Game Changer

As such, analyst Gregg Gilbert cut his estimates for Opdivo to $5 billion in 2017 (from $6 billion) growing to about $8 billion in 2020 (versus about $9 billion earlier). The brokerage had estimated the 1L monotherapy US market opportunity to be about $7 billion.

The analyst also slashed his 2017 revenue forecast to $21.4 billion from $22.6 billion and EPS view to $3.23 from $3.70.

In addition, despite maintaining Hold rating on the stock, Gilbert trimmed his price target to $62 from $68.

That said, the analyst said the company's broad based development strategy for Opdivo includes several tumor types. In 2017, Gilbert anticipates momentum from uptake in pre-treated renal cell carcinoma, classical Hodgkin's lymphoma, and head and neck cancer.

"We also assume continued growth in 2017 in metastatic melanoma and 2L lung indications, although increasing usage of Keytruda in the 1L setting could affect growth in 2L for Opdivo," Gilbert noted.

Shares closed Monday's regular trading session down 4.71 percent on the day at $60.30.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for BMY

DateFirmActionFromTo
Jan 2020ReinstatesBuy
Dec 2019UpgradesHoldBuy
Nov 2019Initiates Coverage OnBuy

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Health Care Price Target Reiteration Analyst Ratings Movers Best of Benzinga

 

Related Articles (BMY)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
YAYOAegis CapitalInitiates Coverage On3.3
ASPNCanaccord GenuityReiterates12.0
FFIVCredit SuisseMaintains160.0
UPSUBSMaintains134.0
FFIVRBC CapitalMaintains147.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com